A Narrative Review on Therapeutic Potentials of Watercress in Human Disorders

Evid Based Complement Alternat Med. 2021 May 7;2021:5516450. doi: 10.1155/2021/5516450. eCollection 2021.ABSTRACTWatercress (WC) is an aquatic vegetable that belongs to the Brassicaceae family, and it often grows near water. In traditional medicine, WC is a known remedy for hypercholesterolemia, hyperglycemia, hypertension, arthritis, bronchitis, diuresis, odontalgia, and scurvy. It also acts as an antiestrogenic and can be used as a nutritional supplement. It has been reported that these therapeutic effects are due to primary metabolites such as isothiocyanates, glucosinolates, polyphenols (flavonoids, phenolic acids, and proanthocyanidins), vitamins (B1, B2, B3, B6, E, and C), terpenes (including carotenoids), and bioelements which exist in this plant. Many pharmacological studies confirm the antioxidant, antibacterial, anticancer, antipsoriatic, anti-inflammatory, cardioprotective, renoprotective, hepatoprotective, and antigenotoxicity effects of WC. The consumption of WC extract can be useful in reducing the complications of hypercholesterolemia and hyperglycemia. Furthermore, the extract of WC could markedly augment the antioxidant enzymes such as superoxide dismutase and catalase activity. Interestingly, consumption of food rich in polyphenols such as WC extract can help reduce oxidative stress, DNA damage, and cancer susceptibility. Several studies also showed that WC extract significantly reduced liver injury as a result of cholestatic hepatic injury, gamma radiation,...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Authors: Source Type: research

Related Links:

HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associat...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson &Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque ps...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
In conclusion, ASHE exerts cytostatic activity on liver cancer cells via both apoptosis and autophagy, and may serve as a potential therapeutic agent for management of liver cancer and autophagy‑related diseases.PMID:33650674 | DOI:10.3892/or.2021.7948
Source: Oncology Reports - Category: Cancer & Oncology Authors: Source Type: research
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion ava...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusion: Natural recovery after TBI may include delayed onset of functional decline or early recovery, followed by progressive deterioration, and is negatively affected by medical comorbidities. Results contribute to the growing evidence that TBI is most appropriately treated as a chronic medical condition complicated by a variety of comorbid conditions.
Source: The Journal of Head Trauma Rehabilitation - Category: Neurology Tags: Original Articles Source Type: research
Asian-Americans fare better than the general population on five different measures of health, according to a new national study.  But though it may appear that the "model minority" myth about the 15 million Asians in America extends even to physical and mental health, experts say this finding obscures the truth about vast disparities between Asian subgroups -- and that the study's methodology may have prevented the elderly, immigrants and people who don't speak English from contributing to a more nuanced picture of the health status of Asians in America.  The report, published by the U.S....
Source: Science - The Huffington Post - Category: Science Source Type: news
Conditions:   Hypertension;   Depression;   Anxiety;   Musculoskeletal Pain;   Arthritis;   Rheumatoid Arthritis;   Osteoporosis;   Chronic Obstructive Pulmonary Disease (COPD);   Asthma;   Chronic Bronchitis;   Cardiovascular Disease;   Heart Failure;   Stroke;   Transient Ischemic Attacks;   Ulcer;   Gastroesophageal Reflux;   Irritable Bowel;   Crohn's Disease;   Ulcerative Colitis;   Diverticulosis;   Chronic Hepatitis;   Diabetes; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acetaminophen | Alternative and Complementary Therapies | Antidoxidants | Arthritis | Bronchitis | Cancer | Cancer & Oncology | Cardiology | Complementary Medicine | Flavonoids | Heart | Hypertension | Liver | Lortab | Nutrition | Rheumatology | Study | Urology & Nephrology | Vegetables | Vitamins | Watercress